Mobility and COVID-19 in Andorra: Country-Scale Analysis of High-Resolution Mobility Patterns and Infection Spread

IEEE J Biomed Health Inform. 2022 Jan;26(1):183-193. doi: 10.1109/JBHI.2021.3121165. Epub 2022 Jan 17.

Abstract

Throughout the COVID-19 pandemic, nonpharmaceutical interventions, such as mobility restrictions, have been globally adopted as critically important strategies to curb the spread of infection. However, such interventions come with immense social and economic costs and the relative effectiveness of different mobility restrictions are not well understood. Some recent works have used telecoms data sources that cover fractions of a population to understand behavioral changes and how these changes have impacted case growth. This study analyzed uniquely comprehensive datasets in order to examine the relationship between mobility and transmission of COVID-19 in the country of Andorra. The data consisted of spatio-temporal telecoms data for all mobile subscribers in the country, serology screening results for 91% of the population, and COVID-19 case reports. A comprehensive set of mobility metrics was developed using the telecoms data to indicate entrances to the country, contact with tourists, stay-at-home rates, trip-making and levels of crowding. Mobility metrics were compared to infection rates across communities and transmission rate over time. All metrics dropped sharply at the start of the country's lockdown and gradually rose again as the restrictions were gradually lifted. Several of these metrics were highly correlated with lagged transmission rate. There was a stronger correlation for measures of indoor crowding and inter-community trip-making, and a weaker correlation for total trips (including intra-community trips) and stay-at-homes rates. These findings provide support for policies which aim to discourage gathering indoors while lifting the most restrictive mobility limitations.

MeSH terms

  • Andorra
  • COVID-19*
  • Communicable Disease Control
  • Humans
  • Pandemics
  • SARS-CoV-2